Clobetasol propionate nanoparticle - Formosa Pharmaceuticals
Alternative Names: APP-13007Latest Information Update: 07 Aug 2024
At a glance
- Originator Activus Pharma; Sosei Heptares
- Developer Formosa Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Antipsoriatics; Antiulcers; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Halogenated hydrocarbons; Propionates
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ocular inflammation; Ocular pain
Most Recent Events
- 05 Aug 2024 Clobetasol propionate nanoparticle licensed to Apotex for Ocular inflammation and Ocular pain in Canada
- 15 May 2024 Eyenovia plans to launch clobetasol propionate nanoparticle for Ocular inflammation and Ocular Pain (Ophthalmic) in August 2024
- 10 May 2024 Clobetasol propionate nanoparticle licensed to Tabuk Pharmaceuticals for Ocular inflammation and Ocular pain